Rani Therapeutics (NASDAQ:RANI - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 5th. Analysts expect Rani Therapeutics to post earnings of ($0.22) per share for the quarter.
Rani Therapeutics (NASDAQ:RANI - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The firm had revenue of $1.03 million during the quarter. On average, analysts expect Rani Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Rani Therapeutics Price Performance
Shares of RANI stock traded up $0.01 on Friday, reaching $1.08. The company's stock had a trading volume of 177,831 shares, compared to its average volume of 745,467. The company has a market capitalization of $62.08 million, a price-to-earnings ratio of -1.02 and a beta of 0.24. The stock's fifty day simple moving average is $1.31 and its 200-day simple moving average is $1.63. The company has a current ratio of 1.60, a quick ratio of 1.60 and a debt-to-equity ratio of 2.34. Rani Therapeutics has a 1 year low of $1.02 and a 1 year high of $7.88.
Analyst Ratings Changes
A number of research firms have recently weighed in on RANI. Canaccord Genuity Group restated a "buy" rating and issued a $9.00 target price on shares of Rani Therapeutics in a report on Wednesday, February 26th. HC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Rani Therapeutics in a research report on Thursday, April 3rd. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $12.33.
Check Out Our Latest Stock Analysis on Rani Therapeutics
Rani Therapeutics Company Profile
(
Get Free Report)
Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.
Recommended Stories
Before you consider Rani Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.
While Rani Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
